For the year ending 2025-12-31, CNTB made $64K in revenue. -$55,005K in net income. Net profit margin of -85945.31%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| License and collaboration revenues | 64 | 26,033 | ||
| Research and development expense | 37,798 | 29,256 | ||
| General and administrative expense | 20,340 | 19,229 | ||
| Total operating expenses | 58,138 | 48,485 | ||
| Loss from operations | -58,074 | -22,452 | ||
| Interest income | 2,268 | 4,453 | ||
| Other income (expense) | 523 | 2,594 | ||
| Total other income, net | 2,791 | 7,047 | ||
| Net loss before income tax | -55,283 | -15,405 | ||
| Income tax expense | 197 | 223 | ||
| Net loss | -55,480 | -15,628 | ||
| Foreign currency translation adjustments | 477 | -670 | ||
| Unrealized gains (losses) on available-for-sale investments | -2 | 12 | ||
| Comprehensive loss | -55,005 | -16,286 | ||
| Basic EPS | -1 | -0.28 | ||
| Diluted EPS | -1 | -0.28 | ||
| Basic Average Shares | 55,660,000 | 55,213,000 | ||
| Diluted Average Shares | 55,660,000 | 55,213,000 | ||
Connect Biopharma Holdings Ltd (CNTB)
Connect Biopharma Holdings Ltd (CNTB)